MUMBAI, India, Jan. 23 -- Intellectual Property India has published a patent application (202511126345 A) filed by Dr. Atul Khajuria; Dr. Pallvi Pandit; Dr. Parmila Malik; Mr. Gagandeep Singh; Dr. Parul Pandit; and Mr. Mahesh Gaba, Hoshiarpur, Punjab, on Dec. 13, 2025, for 'serum metabolite ratio-based biomarker system for early cancer diagnosis and therapeutic response assessment.'
Inventor(s) include Dr. Atul Khajuria; Dr. Pallvi Pandit; Dr. Parmila Malik; Mr. Gagandeep Singh; Dr. Parul Pandit; and Mr. Mahesh Gaba.
The application for the patent was published on Jan. 23, under issue no. 04/2026.
According to the abstract released by the Intellectual Property India: "The invention discloses a Serum Metabolite Ratio-Based Biomarker System for early cancer diagnosis and therapeutic response assessment. The system integrates analytical quantification of serum metabolites, including glucose, lactate, alanine, and glutamine, using LC-MS or NMR, with a computational diagnostic engine that calculates a Metabolite Ratio Index (MRI). The MRI serves as a standardized diagnostic indicator reflecting glucose dysregulation characteristic of cancer metabolism. By comparing computed ratios against pre-established diagnostic thresholds, the system classifies subjects into normal, pre-cancerous, or cancerous categories and enables longitudinal monitoring of therapy response. The invention provides a reproducible, quantitative, and clinically translatable platform combining biochemical analysis with computational intelligence, ensuring enhanced diagnostic accuracy and early detection of cancer."
Disclaimer: Curated by HT Syndication.
